Product image of Multaq (Dronedarone) supplied by GNH India

Multaq

Active Ingredient:
Dronedarone
Origin:
EU

Multaq (Dronedarone)

Dronedarone, the active ingredient in Multaq, is a antiarrhythmic presented as a tablet for oral use. It is used to manage atrial fibrillation and atrial flutter in adult patients.
GNH India supplies Multaq as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Sanofi Winthrop Industrie

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Multaq is an antiarrhythmic medication indicated for rhythm control in atrial arrhythmias.

  • Atrial fibrillation: helps restore and maintain normal sinus rhythm in patients with paroxysmal or persistent AF.
  • Atrial flutter: reduces recurrence of flutter episodes and supports rhythm stabilization.
  • Maintenance of sinus rhythm: used as a long‑term strategy to prevent arrhythmia relapse after cardioversion.

How It Works

  • Dronedarone acts as a multi‑channel blocker, inhibiting sodium (Na+), potassium (K+), and calcium (Ca2+) currents while prolonging cardiac repolarization. This combined effect reduces the excitability of atrial tissue, suppresses abnormal automaticity, and stabilizes the myocardial action potential, thereby decreasing the likelihood of atrial fibrillation and flutter recurrence.

Side Effects

Adverse reactions may occur with dronedarone therapy.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: loose stools occurring intermittently.
  • Fatigue: general tiredness or reduced energy.
  • Headache: occasional mild headache.
  • Dizziness: transient light‑headedness.
  • Elevated liver enzymes: mild, reversible increase in ALT/AST.

Serious or Rare Side Effects

  • Hepatotoxicity: severe liver injury requiring monitoring.
  • Pulmonary toxicity: interstitial lung disease or fibrosis.
  • Bradycardia: clinically significant slowing of heart rate.
  • QT prolongation: risk of torsades de pointes.
  • Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Thromboembolic events: rare but serious clot formation.

Precautions & Warnings

Before initiating dronedarone, clinicians should assess patient suitability and monitor for potential risks.

  • Contraindication in pregnancy: drug is classified as Category X; avoid use in pregnant women.
  • Avoid in severe hepatic impairment: may exacerbate liver dysfunction.
  • Caution in heart failure: can worsen symptoms in NYHA class IV patients.
  • Monitor electrolytes: maintain potassium and magnesium within normal range.
  • Regular ECG checks: assess QT interval and heart rate.
  • Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Dronedarone interacts with several drug classes that can alter its safety profile.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase dronedarone levels and toxicity.
  • Digoxin: dronedarone raises digoxin concentrations, risking arrhythmia.
  • Anticoagulants (warfarin, dabigatran): enhanced anticoagulant effect, requiring dose adjustment.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: additive bradycardia; monitor heart rate.
  • Calcium channel blockers (verapamil, diltiazem): may increase plasma dronedarone.
  • Statins (simvastatin, atorvastatin): higher risk of myopathy; consider dose reduction.

Frequently Asked Questions

Multaq contains dronedarone, an antiarrhythmic medication prescribed to restore and maintain normal heart rhythm in adults with atrial fibrillation or atrial flutter. It is used as a rhythm‑control strategy after cardioversion or for long‑term prevention of arrhythmia recurrence.

Dronedarone blocks multiple cardiac ion channels—including sodium, potassium, and calcium channels—while prolonging the repolarization phase of the cardiac action potential. This multi‑channel inhibition reduces abnormal electrical activity in the atria, helping to prevent episodes of atrial fibrillation and flutter.

The specific dosing regimen for Multaq is determined by the prescribing physician based on the patient’s clinical condition, renal and hepatic function, and concomitant medications. Dosing instructions are individualized and should follow the prescriber’s order.

Multaq (dronedarone) is classified as Pregnancy Category X, indicating it is contraindicated in pregnancy because of potential fetal harm. It is also not recommended for breastfeeding mothers, as it may pass into breast milk and affect the infant.

To request Multaq, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details, and any necessary import documentation.

Compared with older class III agents like amiodarone, dronedarone has a lower risk of thyroid and pulmonary toxicity but may be less potent in some patients. Its multi‑channel blocking profile offers a balanced efficacy‑safety profile, making it suitable for patients who cannot tolerate amiodarone’s long‑term adverse effects.

Multaq tablets should be stored at ambient temperature, below 25 °C, in the original blister pack. Keep the medication away from moisture, direct sunlight, and excessive heat to maintain stability and potency.

Multaq is taken orally, usually once daily with food to improve absorption. The tablet should be swallowed whole with a full glass of water and not crushed or chewed.

Serious risks include hepatotoxicity, severe lung disease, significant bradycardia, QT‑interval prolongation leading to torsades de pointes, and rare thromboembolic events. Patients should be monitored regularly for liver function, pulmonary symptoms, and cardiac rhythm.

Multaq is contraindicated in patients with permanent atrial fibrillation, severe heart failure (NYHA class IV), significant hepatic impairment, and in pregnant or breastfeeding women. It should also be avoided in individuals taking strong CYP3A4 inhibitors or those with known hypersensitivity to dronedarone.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Dronedarone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT